AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Clinicaltrialvanguard

Published November 8, 2026 · Updated November 10, 2026

Psychedelic Trials Need Better Blinding: What UMBRAA Could Contribute

Read the full story at Clinicaltrialvanguard

The MAPS MDMA- assisted therapy ... In my role overseeing clinical care at Mindbloom, where more than 800,000 ketamine treatment sessions have been.

Post on X

Share this story

Surfaced by this Google Alert

Ketamine therapy